RecruitingNCT06967480

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

MG-EVOLUTION. Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis: A Real-World Study With Biomarker Analysis

Sponsor

Alexion Pharmaceuticals, Inc.

Enrollment

40 participants

Start Date

Jul 31, 2025

Study Type

OBSERVATIONAL

Conditions

Generalized Myasthenia Gravis Anti-AChR Antibody Positive

Summary

The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ravulizumab for people with anti-achr antibody positive and generalized myasthenia gravis. The study is currently recruiting participants at 23 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRavulizumab

Participants will receive Ravulizumab.

Locations(23)

Clinical Trial Site

Bergamo, Italy

Clinical Trial Site

Bologna, Italy

Clinical Trial Site

Bologna, Italy

Clinical Trial Site

Brescia, Italy

Clinical Trial Site

Florence, Italy

Clinical Trial Site

Imperia, Italy

Clinical Trial Site

Lecco, Italy

Clinical Trial Site

Messina, Italy

Clinical Trial Site

Milan, Italy

Clinical Trial Site

Milan, Italy

Clinical Trial Site

Naples, Italy

Clinical Trial Site

Novara, Italy

Clinical Trial Site

Orbassano, Italy

Clinical Trial Site

Padova, Italy

Clinical Trial Site

Palermo, Italy

Clinical Trial Site

Parma, Italy

Clinical Trial Site

Pavia, Italy

Clinical Trial Site

Pisa, Italy

Clinical Trial Site

Roma, Italy

Clinical Trial Site

Salerno, Italy

Clinical Trial Site

San Giovanni Rotondo, Italy

Clinical Trial Site

Sassari, Italy

Clinical Trial Site

Torino, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06967480

Related Trials

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587145 locations

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

NCT069875394 locations

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT0619388922 locations

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT060559599 locations

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

NCT0670426911 locations